Daiichi Sankyo Ltd ADR (DSNKY)

$19.02 +0.86 (4.73%)
Market Cap 34.40B
Revenue (ttm) 12.45B
Net Income (ttm) 1.95B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 16.86
Profit Margin 15.68%
Debt to Equity Ratio 0.13
Volume 915,700
Avg Vol 556,036
Day's Range N/A - N/A
Shares Out 1.89B
Stochastic %K 57%
Beta N/A
Analysts Strong Sell
Price Target $34.15

Company Profile

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an inter...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 81 3 6225 1111
Address:
3-5-1, Nihonbashi-honcho, Chuo, Japan
Quantumup
Quantumup Apr. 1 at 4:42 PM
Truist reiterated $NUVB Buy; $12 $DSNKY DSKYF $HCM BAYRY LLY RIGL Here's what Truist said in its note: https://x.com/Quantumup1/status/2039382081814286759?s=20
1 · Reply
Belisimo
Belisimo Mar. 24 at 12:37 PM
$DSNKY lol now the other way. Some idiot playing
0 · Reply
Belisimo
Belisimo Mar. 24 at 11:07 AM
$DSNKY Misleading quote??? Where are they getting this stock price from?
0 · Reply
Broview
Broview Mar. 19 at 7:30 AM
$DSNKY adding ? Recession proof sector?
0 · Reply
Broview
Broview Mar. 3 at 12:23 PM
$DSNKY Enhertu star? $AZN ? Keep adding? Be contrarian? Be lonesome?
0 · Reply
Broview
Broview Feb. 21 at 10:28 AM
$DSNKY loading?
0 · Reply
Broview
Broview Feb. 18 at 9:02 AM
$DSNKY top player oncology research?
0 · Reply
Quantumup
Quantumup Feb. 17 at 12:08 PM
Citizens🏁 $IMMP and said, We are initiating coverage of Immutep Limited with a Market Outperform rating and $6 price target based on a revenue and earnings multiple analysis. $MRK AUTL ALLO ANL $SMMT $DSNKY - AZN BMY $NUVL Here's what else Citizens had to say: https://x.com/Quantumup1/status/2023730370282197356?s=20
0 · Reply
JuggernautRaider
JuggernautRaider Dec. 28 at 11:42 PM
Nice work in 2025, $NUVB $JAZZ $AMGN $DSNKY (and others) 👍 🫁 but countless Lung cancer patients are still waiting ⏰ @BioCapitalist99 and @Biotech_Beast know
0 · Reply
Broview
Broview Dec. 13 at 4:49 PM
$DSNKY decent pharmaceuticals?
0 · Reply
Latest News on DSNKY
No data available.
Quantumup
Quantumup Apr. 1 at 4:42 PM
Truist reiterated $NUVB Buy; $12 $DSNKY DSKYF $HCM BAYRY LLY RIGL Here's what Truist said in its note: https://x.com/Quantumup1/status/2039382081814286759?s=20
1 · Reply
Belisimo
Belisimo Mar. 24 at 12:37 PM
$DSNKY lol now the other way. Some idiot playing
0 · Reply
Belisimo
Belisimo Mar. 24 at 11:07 AM
$DSNKY Misleading quote??? Where are they getting this stock price from?
0 · Reply
Broview
Broview Mar. 19 at 7:30 AM
$DSNKY adding ? Recession proof sector?
0 · Reply
Broview
Broview Mar. 3 at 12:23 PM
$DSNKY Enhertu star? $AZN ? Keep adding? Be contrarian? Be lonesome?
0 · Reply
Broview
Broview Feb. 21 at 10:28 AM
$DSNKY loading?
0 · Reply
Broview
Broview Feb. 18 at 9:02 AM
$DSNKY top player oncology research?
0 · Reply
Quantumup
Quantumup Feb. 17 at 12:08 PM
Citizens🏁 $IMMP and said, We are initiating coverage of Immutep Limited with a Market Outperform rating and $6 price target based on a revenue and earnings multiple analysis. $MRK AUTL ALLO ANL $SMMT $DSNKY - AZN BMY $NUVL Here's what else Citizens had to say: https://x.com/Quantumup1/status/2023730370282197356?s=20
0 · Reply
JuggernautRaider
JuggernautRaider Dec. 28 at 11:42 PM
Nice work in 2025, $NUVB $JAZZ $AMGN $DSNKY (and others) 👍 🫁 but countless Lung cancer patients are still waiting ⏰ @BioCapitalist99 and @Biotech_Beast know
0 · Reply
Broview
Broview Dec. 13 at 4:49 PM
$DSNKY decent pharmaceuticals?
0 · Reply
redistributeW
redistributeW Oct. 1 at 10:35 PM
$DSNKY Misinformation
0 · Reply
Quantumup
Quantumup Sep. 23 at 1:12 PM
UBS reiterated $IDYA at Buy-$50-Top Pick and said, we believe $IDYA's lead asset, darovasertib (daro), is a transformative therapy for uveal melanoma, yet underappreciated by the market - we est a $1.3B peak sales potential while the Street is pricing in $800M peak at the current stock price. We believe daro's impressive clinical efficacy, clean safety, and convenient oral dosing could enable its use over the current standard of care in front-line and neoadjuvant uveal melanoma. More importantly, we see several high conviction near-term catalysts over the next 6 months that could drive significant upside for the stock. These include 1) daro Phase 2 readout in neoadjuvant enucleation cohort at ESMO medical conference (Oct 17-21), 2) daro Phase 2 overall survival data in 1L metastatic uveal melanoma at SMR medical conference (Oct 25-28), and 3) daro pivotal Phase 3 data in 1L metastatic uveal melanoma (HLA-A2-) in 4Q25-1Q26. $GILD $SMMT $BNTX $DSNKY
0 · Reply
Im_a_realist
Im_a_realist Sep. 7 at 3:24 PM
$DSNKY Might be a runner come Monday morning: https://finance.yahoo.com/news/ifinatamab-deruxtecan-demonstrated-clinically-meaningful-144500277.html
0 · Reply
Quantumup
Quantumup Sep. 4 at 12:56 PM
Barclays🏁 $IDYA Overweight/$40. Citizens🏁 $IDYA Market Outperform/$41. $ZLAB $AMGN $DSNKY $PFE GILD AZN RHHBY Barclays and Citizens JMP said in their initiation reports:
0 · Reply
Quantumup
Quantumup Sep. 3 at 12:13 PM
JPMorgan⬆️ $IDYA $74 from $72/reit'd OW ~it believes $IDYA's early-stage updates for IDE849 / IDE397 can drive investor interest in the pipeline beyond darovasertib. $PFE $GILD $DSNKY $AZN RHHBY JPMorgan said in its note to investors: IDEAYA Biosciences is an emerging company in the precision-oncology space. Importantly, Ideaya's lead asset, darovasertib (IDE196), has established proof-of-concept (POC) within uveal melanoma. Net-net, we continue to see darovasertib, especially in the metastatic uveal melanoma (MUM) setting, as de-risked. On the broader pipeline beyond darovasertib in MUM, it is "choose your favorite adventure scenario", which provides interesting long-term optionality (we think darovasertib in neoadjuvant is underappreciated). Looking forward, we anticipate focus on updates for darovasertib (metastatic / neoadjuvant settings), IDE397, and IDE849 programs. Our Overweight rating on $IDYA shares is based on the potential of darovasertib and broad synthetic lethality pipeline.
0 · Reply
Broview
Broview Aug. 31 at 3:12 PM
$DSNKY firmly long Japanese stocks?
0 · Reply
RichieS
RichieS Aug. 29 at 4:55 PM
$DSNKY Here's a more promising investment than $IVF Merck MRK and Japan’s Daiichi Sankyo announced the dosing of the first patient in the phase III HERTHENA-Breast04 study evaluating their investigational HER3-directed DXd antibody-drug conjugate (ADC), patritumab deruxtecan (HER3-DXd), for treating certain patients with breast cancer. https://finance.yahoo.com/news/mrk-daiichi-begin-phase-iii-151300884.html
0 · Reply
redistributeW
redistributeW Aug. 19 at 9:17 PM
$DSNKY ST misleading after-hours quote? What is this???
0 · Reply
Quantumup
Quantumup Jul. 22 at 12:05 PM
TD Cowen🏁 $IDYA at a Buy rating. $PFE $GILD $DSNKY $AZN RHHBY TD Cowen in its initiation report said, "IDEAYA's pipeline — with soon-to-be 9 clinical-stage programs — represents the best of targeted oncology and is led by a world-class team. The lead daro + criz combo should launch in 2026 in mUM, with a high likelihood of success in neoadjuvant. Near-term DLL3 ADC data are likely to be strong, and MAT2A efficacy should add to Trodelvy with NT data. We initiate at Buy given the very attractive EV."
0 · Reply
Quantumup
Quantumup Jul. 9 at 2:54 PM
RBC⬇️ $IDYA PT to $30 from $57, reiterated at OP and said "Ph.III Readout in 2H25 Should Drive Upside and Unlock A $1B Revenue Oppt'y; We are updating our views on $IDYA following additional diligence, KOL discussions, and meeting with mgmt" $MRK $DSNKY $ZLAB $ONC PFE GILD RBC Capital added, "While the stock has been largely range bound this year, with less investor attention, we believe as we enter the second half $IDYA should garner more attention given a major ph.Ill event for lead drug daro, as well as a number of supporting pipeline updates. We see a 65%+ likelihood of success for the ph.Ill readout in metastatic uveal melanoma coming towards year-end, and see 40% upside given potential for a rapid launch by 2026. With a lower risk and high reward catalyst, as well as pipeline clarity across '897 and '349, we would be buyers into 2H25; tgt to $30 and maintaining Outperform, Spec. Risk rating."
0 · Reply
Quantumup
Quantumup Jun. 26 at 11:38 AM
Wells Fargo🏁 $IDYA OW-$44~thinks the Street isn't pricing in enough value for daro's pot'l in UM - '25 updates should de-risk Tx in both first-line mUM & the neo adjuvant setting - updates from early pipeline should offer upside in the next 12-18mo. $MRK $GILD PFE $DSNKY $XBI Wells Fargo said in its $IDYA initiation note: "Shares are down -15% YTD vs $XBI -8% and believe the stock isn't pricing in daro's oppty at these levels. We like the setup over the next 12 mos, where the co plans to provide several data points for daro both in the metastatic and neoadjuvant settings that should get investors more confident on its potl in UM. Further, there is a good chance daro's pivotal mPFS readout is pos (65%), which could lead to an accelerated approval and launch in 2026 in 1L MUM."
0 · Reply
redistributeW
redistributeW Jun. 24 at 10:23 PM
$DSNKY staholah
0 · Reply